NOTICE OF PARTIAL REFUND

Ipsen Biopharmaceuticals, Inc. ("Ipsen") is posting this notice to inform 340B Covered Entities that purchased Somatuline® Depot (lanreotide) (NDCs 15054-1060 (60mg), 15054-1090 (90mg), and 15054-1120 (120mg)) between January 1, 2015 and June 30, 2015 that they may be eligible for partial refunds of their purchases.

Specifically, as a result of an update to the base date AMP for Somatuline® Depot, the 340B ceiling price for Somatuline® Depot was reduced, requiring partial refunds to Covered Entities that, during this period, purchased Somatuline® Depot at the then-prevailing ceiling price.

Ipsen has made the necessary partial refunds to over ninety-percent of impacted Covered Entities through its specialty distributors, but has been unable to identify the Covered Entities to which the remaining refunds are owed due to the age of the claims and the associated chargeback data.

Any Covered Entity that believes it is entitled to a partial refund (for which it has not already received a refund) should submit a claim to Ipsen by email using the following information:

Karen McRae
Director, Government Pricing
Karen.mcrae@ipsen.com

Please provide documentation to support the purchase, including the identity of the purchasing entity, date of purchase, number of units purchased by NDC, and purchase price, along with any additional documentation that you believe will substantiate the claim.

Claims for partial refunds must be received by Ipsen no later than July 1, 2022.

Ipsen will research each claim based on the information provided, comparing it to available chargeback data and records of refunds previously paid. Eligible claims will be promptly paid by check.

Thank you.